Co-targeting CDK4/6 and BRD4 promotes senescence and ferroptosis sensitivity in cancer
Xianbing Zhu,Zheng Fu,Kendall Dutchak,Azadeh Arabzadeh,Simon Milette,Jutta Steinberger,Geneviève Morin,Anie Monast,Virginie Pilon,Tim Kong,Bianca N Adams,Erika Prando Munhoz,Hannah Jb Hosein,Tianxu Fang,Jing Su,Yibo Xue,Roni Rayes,Veena Sangwan,Logan A Walsh,Guojun Chen,Daniela F Quail,Jonathan D Spicer,Morag Park,David Dankort,Sidong Huang,Bianca N. Adams,Hannah JB. Hosein,Logan A. Walsh,Daniela F. Quail,Jonathan D. Spicer
DOI: https://doi.org/10.1158/0008-5472.can-23-1749
IF: 11.2
2024-01-27
Cancer Research
Abstract:Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for breast cancer treatment and show activity against other malignancies, including KRAS-mutant non-small cell lung cancer (NSCLC). However, the clinical efficacy of CDK4/6 inhibitors is limited due to frequent drug resistance and their largely cytostatic effects. Through a genome-wide cDNA screen, we identified that bromodomain-containing protein 4 (BRD4) overexpression conferred resistance to the CDK4/6 inhibitor palbociclib in KRAS-mutant NSCLC cells. Inhibition of BRD4, either by RNA interference or small-molecule inhibitors, synergized with palbociclib to induce senescence in NSCLC cells and tumors, and the combination prolonged survival in a KRAS-mutant NSCLC mouse model. Mechanistically, BRD4-inhibition enhanced cell cycle arrest and reactive oxygen species (ROS) accumulation, both of which are necessary for senescence induction; this in turn elevated GPX4, a peroxidase that suppresses ROS-triggered ferroptosis. Consequently, GPX4 inhibitor treatment selectively induced ferroptotic cell death in the senescent cancer cells, resulting in tumor regression. Co-targeting CDK4/6 and BRD4 also promoted senescence and ferroptosis vulnerability in pancreatic and breast cancer cells. Together, these findings reveal therapeutic vulnerabilities and effective combinations to enhance the clinical utility of CDK4/6 inhibitors.
oncology